1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
Global Molecular Diagnostics Industry

Global Molecular Diagnostics Industry

  • April 2021
  • 880 pages
  • ID: 90566
  • Format: PDF
  • Global Industry Analysts


Table of Contents


Timely market intelligence is paramount in these uncertain times!

We launched an impact survey to update this project with timely insights during 2020. Update frequency will depend upon evolving market conditions and executive opinions. Our participants are executives driving strategy, marketing, sales and product management at competitive companies worldwide. All updates during the rest of the year are complimentary to clients!

- With PCR Tests Considered as the Gold Standard of Covid-19 Testing, Molecular Diagnostics Sees a 20.7% Spike in Revenues
- The global market for Molecular Diagnostics is expected witness revenues spike by 20.7% in the year 2020 and thereafter continue to grow and reach US$19.9 billion by the year 2027, trailing a post COVID-19 CAGR of 9.8% over the analysisperiod2020 through 2027. Molecular diagnostic testing for COVID-19 is rapidly evolving each week as global infections continue to surge. Countries worldwide are stepping up testing rates significantly in a bid to control the spread of infections & mortality rates. India which is now in the eye of the pandemic storm is currently carrying out 1 million COVID-19 tests daily. The pressing requirement for massive and universal testing is leading to introduction of various technologies for COVID-19 diagnostics, providing access to new tests in response to the pandemic. These diagnostic techniques, along with approaches to develop new vaccines or therapies, rely heavily on molecules from the coronavirus, including nucleic acids such as DNA or RNA and proteins. COVID-19 diagnostics essentially screen samples for the viral RNA or the presence of antibodies for viral RNA. While viral RNA tests identify presence of SARS-CoV-2 infection from swab samples by reverse transcription of polymerase chain reaction (RT-PCR), immunoassay-based antibody tests delve deeper into the serum and diagnose presence of antibodies produced in the body and quantify the impact and resultant immunity attained. While RT-PCR tests are direct tests, antibody tests are to be paired with viral RNA tests and are not conclusive on their own and sometimes yield inconsistent results if the individual’s immune system produces antibodies later than the time of the test.
- As the gold standard in molecular diagnostics, PCR isa dominant way through which global healthcare systems are testing for Covid-19. These tests work by detecting the viral genomic material of the virus namely ribonucleic acid (RNA) which remains in the body while the virus replicates. Testing for COVID-19 detects genetic material of the virus from the lower and upper respiratory tract. Molecular tests use swab collection of the specimen from the mouth or nose of a person. The specimen is processed for the specific ribonucleic acid (RNA) or genetic signature of the SARS-CoV-2. Molecular tests are commonly used in acute respiratory infections for detecting the viral genetic material in specimens. The approach relies on reverse transcription polymerase chain reaction (RT-PCR) that involves copying and comparison of the genetic material from a specimen to the virus’ genetic sequence. Molecular testing uses swab or saliva samples to detect the virus. The swab test involves insertion of a six inch swab into the back side of the nasal passage. The swab is rotated several times for collecting the sample from both nostrils, which is sent to a laboratory for testing. Abbott Laboratories has launched a point-of-care swab test intended to deliver test results in around five minutes. The availability of point-of-care or portable test kits allows sample collection in provider offices and even at a drive-thru site.
- The FDA has recently authorized the foremost molecular test that considers saliva specimen. Offered by Rutgers’ RUCDR Infinite Biologics, the test is accurate and addresses shortage of swabs. The FDA has allowed several companies to distribute molecular tests and notified various players to start testing people using internally-validated tests. Molecular diagnostics are gaining growing confidence in COVID 19 testing by virtue of their high specificity and accuracy RT-PCR tests in comparison with the cost efficient alternative - antibody tests that falter at authenticity of findings due to inconclusive early stage viral presence. The phenomenal rise in the COVID cases worldwide is poised to grow the market for molecular diagnostics multi-fold. With the recovery across the Asian, European and American markets falling into different stages, it is vital for the molecular diagnostics companies to be present in the right markets at the right time, vet their resources, scale up production, and optimize supply chains to overcome market specific hurdles, shortages, supply disruptions to pocket healthy volumes as long as the demand exists. Volumes may recede as the global infections go down gradually, or are contingent upon the development of the vaccine by 2021. In the post COVID-19 period, demand for molecular diagnostics will grow stronger with pent-up demand for infectious disease testing such as tuberculosis, hepatitis C, hepatitis B, HPV, and also STDs.

- Select Competitors (Total 84 Featured) -
  • Abbott Laboratories
  • Abbott Molecular
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Cepheid
  • F. Hoffmann-La Roche Ltd.
  • Grifols International, S.A.
  • Hologic, Inc.
  • QuestDiagnostics, Inc.
  • Siemens Healthcare GmbH
  • Tecan Group Ltd.
  • The ELITechGroup
  • Thermo Fisher Scientific

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Drugs For Benign Prostatic hypertrophy Global Market Report 2021: COVID 19 Impact and Recovery to 2030

  • $ 5000
  • April 2021
  • 175 pages

Major players in the drugs for benign prostatic hypertrophy market are Roche Ltd, Hologic, QIAGEN, Abbott, and Danaher Corporation. The global drugs for benign prostatic hypertrophy market is expected ...

  • World
  • United States
  • Molecular Diagnostics
  • Industry analysis
  • Drug Approval


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on